Next Article in Journal
Short-Term Drop in Antibody Titer after the Third Dose of SARS-CoV-2 BNT162b2 Vaccine in Adults
Next Article in Special Issue
Vulnerability Predictors of Post-Vaccine SARS-CoV-2 Infection and Disease—Empirical Evidence from a Large Population-Based Italian Platform
Previous Article in Journal
Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study
Previous Article in Special Issue
The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates
 
 
Article

Article Versions Notes

Vaccines 2022, 10(5), 808; https://doi.org/10.3390/vaccines10050808
Action Date Notes Link
article pdf uploaded. 19 May 2022 16:17 CEST Version of Record https://www.mdpi.com/2076-393X/10/5/808/pdf-vor
article xml file uploaded 20 May 2022 09:36 CEST Original file -
article xml uploaded. 20 May 2022 09:36 CEST Update -
article pdf uploaded. 20 May 2022 09:36 CEST Updated version of record https://www.mdpi.com/2076-393X/10/5/808/pdf-vor
article html file updated 20 May 2022 09:37 CEST Original file -
article xml file uploaded 20 May 2022 09:38 CEST Update -
article xml uploaded. 20 May 2022 09:38 CEST Update -
article pdf uploaded. 20 May 2022 09:38 CEST Updated version of record https://www.mdpi.com/2076-393X/10/5/808/pdf-vor
article html file updated 20 May 2022 09:40 CEST Update -
article xml file uploaded 25 May 2022 08:19 CEST Update -
article xml uploaded. 25 May 2022 08:19 CEST Update https://www.mdpi.com/2076-393X/10/5/808/xml
article pdf uploaded. 25 May 2022 08:19 CEST Updated version of record https://www.mdpi.com/2076-393X/10/5/808/pdf
article html file updated 25 May 2022 08:21 CEST Update https://www.mdpi.com/2076-393X/10/5/808/html
Back to TopTop